Agios Pharmaceuticals, Inc. (AGIO)
After hours:
Chart Events
Performance Outlook
| Previous Close | 22.55 |
| Open | 22.62 |
| Bid | 22.89 x 1200 |
| Ask | 24.52 x 900 |
| Day's Range | 22.62 - 23.38 |
| 52 Week Range | 16.75 - 34.76 |
| Volume | |
| Avg. Volume | 541,883 |
| Market Cap | 1.27B |
| Beta (5Y Monthly) | 0.96 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.20 |
| Earnings Date | May 03, 2023 - May 08, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 37.80 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for AGIO
Related Research
- Agios Pharmaceuticals, Inc.JAZZ: Raising target price to $157.00JAZZ PHARMACEUTICALS PLC has an Investment Rating of BUY; a target price of $157.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.RatingFair ValueEconomic Moat3 days agoArgus Research
- InvestorPlace
7 Biotech Stocks That Could Be the Next Big Thing
While the concept of high-risk speculation seems particularly dangerous at this juncture, gamblers may nevertheless want to consider the merits of targeting potentially lucrative biotech stocks that could be the next big thing. These lesser-known enterprises may not command worldwide attention at the moment. Nevertheless, they could yield tremendous profitability if they come through. Another factor that benefits high-risk, high-reward biotech stocks centers on the underlying sector’s permanent
- Simply Wall St.
We're Hopeful That Agios Pharmaceuticals (NASDAQ:AGIO) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
- TipRanks
TipRanks ‘Perfect 10’ List: These 2 Healthcare Stocks Look Compelling at Current Levels
With two full months of 2023 behind us, it’s hard to say just how this year is going to shape up. January saw a strong rally, while February was volatile and market analysts and economists are still debating where the long-term trends will head. But what can the retail investor do, while the professionals are debating? A turn to the data may yield some answers – and give clues toward compelling stocks. The Smart Score data tool from TipRanks is specially designed to cut through the fog of uncert
